Fig. 5From: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilatorMean change from baseline in QTcF over time (safety population). Data are LS means ± standard error. QTcF = QT interval corrected for heart rate using the Fridericia formula; LS = least squaresBack to article page